Routine interval computed tomography to detect new soft-tissue disease might be unnecessary in patients with androgen-independent prostate cancer and metastasis only to bone

BJU International

Volumn 99, Issue 3, 2007, Pages 525-528

  Wu, Shenhong L ^a   Jones, Elizabeth ^a   Gulley, James L ^a   Arlen, Philip M ^a   Chen, Clara C ^a   Figg, William D ^a   Dahut, William L ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Androgen independent prostate cancer; Bone metastasis; CT; Soft tissue metastasis

Indexed keywords

ALENDRONIC ACID; ANDROGEN; CANCER VACCINE; DOCETAXEL; KETOCONAZOLE; PROSTATE SPECIFIC ANTIGEN; THALIDOMIDE;

ADULT; AGED; ARTICLE; BONE METASTASIS; BONE SCINTISCANNING; CANCER CYTODIAGNOSIS; CANCER PATIENT; CLINICAL PROTOCOL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; COURSE EVALUATION; DISEASE COURSE; FOLLOW UP; HUMAN; ILIAC BONE; LYMPHADENOPATHY; MAJOR CLINICAL STUDY; MALE; PATIENT ASSESSMENT; PRIORITY JOURNAL; PROSTATE CANCER; RETROSPECTIVE STUDY; SOFT TISSUE; SOFT TISSUE METASTASIS;

ADULT; AGED; AGED, 80 AND OVER; ANDROGENS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE NEOPLASMS; DISEASE PROGRESSION; HUMANS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; SOFT TISSUE NEOPLASMS; TOMOGRAPHY, X-RAY COMPUTED; UNNECESSARY PROCEDURES;

EID: 33846917748     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2006.06654.x     Document Type: Article

References (25)

1. Jemal A, Siegel R, Ward E et al. Cancer statistics, 2006. CA Cancer J Clin 2006; 56: 106-30
2. Crawford ED, Eisenberger MA, McLeod DG et al. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 1989; 321: 419-24
3. Sharifi N, Gulley JL, Dahut WL. Androgen deprivation therapy for prostate cancer. JAMA 2005; 294: 238-44
4. Eisenberger MA, Blumenstein BA, Crawford ED et al. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med 1998; 339: 1036-42
5. Petrylak DP, Tangen CM, Hussain MH et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004; 351: 1513-20
6. Tannock IF, de Wit R, Berry WR et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351: 1502-12
7. Figg WD, Ammerman K, Patronas N et al. Lack of correlation between prostate-specific antigen and the presence of measurable soft tissue metastases in hormone-refractory prostate cancer. Cancer Invest 1996; 14: 513-7
8. Bubendorf L, Schopfer A, Wagner U et al. Metastatic patterns of prostate cancer: an autopsy study of 1589 patients. Hum Pathol 2000; 31: 578-83
9. Rubin MA, Putzi M, Mucci N et al. Rapid ('warm') autopsy study for procurement of metastatic prostate cancer. Clin Cancer Res 2000; 6: 1038-45
10. Singh D, Yi WS, Brasacchio RA et al. Is there a favorable subset of patients with prostate cancer who develop oligometastases? Int J Radiat Oncol Biol Phys 2004; 58: 3-10
11. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-16
12. Arlen PM, Gulley JL, Parker C et al. A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer. Clin Cancer Res 2006; 12: 1260-9
13. Dahut WL, Gulley JL, Arlen PM et al. Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer. J Clin Oncol 2004; 22: 2532-9
14. Figg WD, Liu Y, Arlen P et al. A randomized, phase II trial of ketoconazole plus alendronate versus ketoconazole alone in patients with androgen independent prostate cancer and bone metastases. J Urol 2005; 173: 790-6
15. Bubley GJ, Carducci M, Dahut W et al. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol 1999; 17: 3461-7
16. Scher HI, Morris MJ, Kelly WK, Schwartz LH, Heller G. Prostate cancer clinical trial end points: 'RECIST'ing a step Clin Cancer Res 2005; 11: 5223-32
17. Logothetis CJ, Lin SH. Osteoblasts in prostate cancer metastasis to bone. Nat Rev Cancer 2005; 5: 21-8
18. Tantivejkul K, Kalikin LM, Pienta KJ. Dynamic process of prostate cancer metastasis to bone. J Cell Biochem 2004; 91: 706-17
19. Shah RB, Mehra R, Chinnaiyan AM et al. Androgen-independent prostate cancer is a heterogeneous group of diseases: lessons from a rapid autopsy program. Cancer Res 2004; 64: 9209-16
20. Furuya Y, Akakura K, Akimoto S, Inomiya H, Ito H. Pattern of progression and survival in hormonally treated metastatic prostate cancer. Int J Urol 1999; 6: 240-4
21. Jorgensen T, Muller C, Kaalhus O, Danielsen HE, Tveter KJ. Extent of disease based on initial bone scan: important prognostic predictor for patients with metastatic prostatic cancer. Experience from the Scandinavian Prostatic Cancer Group Study No. 2 (SPCG-2). Eur Urol 1995; 28: 40-6
22. Yamashita K, Denno K, Ueda T et al. Prognostic significance of bone metastases in patients with metastatic prostate cancer. Cancer 1993; 71: 1297-302
23. Nakamachi H, Suzuki H, Akakura K et al. Clinical significance of pulmonary metastases in stage D2 prostate cancer patients. Prostate Cancer Prostatic Dis 2002; 5: 159-63
24. Rao QA, Newhouse JH. Risk of nephropathy after intravenous administration of contrast material: a critical literature analysis. Radiology 2006; 239: 392-7
25. Faulkner K, Moores BM. Radiation dose and somatic risk from computed tomography. Acta Radiol 1987; 28: 483-8